Evidence map›Paper›PMID 32904486›Full record

ArticleCase reports in dermatological medicine2020

Atypical Presentation of Post-Kala-Azar Dermal Leishmaniasis in Bhutan.

Ambika Pradhan, Tashi Tobgay, Sithar Dorjee, Tenzin Wangdi, Guofa Zhou, Nadira D Karunaweera

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in dermatological medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. An Update on Clinical and Pathogenic Spectra of Leishmaniasis.Expert reviews in molecular medicine · 2025
    Review
  4. Review
  5. Unusual Observations in Leishmaniasis-An Overview.Pathogens (Basel, Switzerland) · 2023
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Ambika PradhanJigmi Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan.
Tashi TobgayKhesar Gyalpo University of Medical Sciences of Bhutan, Thimphu, Bhutan.ORCID https://orcid.org/0000-0001-9787-3841
Sithar DorjeeKhesar Gyalpo University of Medical Sciences of Bhutan, Thimphu, Bhutan.
Tenzin WangdiVector-borne Disease Control Programme, Ministry of Health, Thimphu, Bhutan.
Guofa ZhouProgram in Public Health, University of California, Irvine, CA, USA.
Nadira D KarunaweeraDepartment of Parasitology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.ORCID https://orcid.org/0000-0003-3985-1817
Khesar Gyalpo University of Medical Sciences of Bhutan · BTRoyal Centre for Disease Control · BTUniversity of California, Irvine · USUniversity of Colombo · LK

Funding

Epidemiology and transmission of Leishmania donovani infections in Sri Lanka and BhutanU01AI136033 · NIAID · UNIVERSITY OF COLOMBO · PI KARUNAWEERA, NADIRA DHARSHANI, ZHOU, GUOFA · 2017 to 2021
$2.0M
NIAID NIH HHS U01 AI136033
6 · The paper itself

Abstract

This article describes an atypical case of post-kala-azar dermal leishmaniasis associated with complications due to delayed diagnosis and poor case management. The grave consequences of the prolonged disease process that continued for over 2 decades with eventual healing included facial disfigurement, visual impairment, and mental distress both to the patient and the family. The persistent infection within the skin over a lengthy period with likely increased risk of infection spread in the community highlights its potential negative impact on the ongoing leishmaniasis elimination program in the Indian subcontinent. Bhutan is a member of the leishmaniasis elimination network in Asia, and the government continues to invest in maintenance of the national healthcare system. The case study reveals the gaps in the healthcare system with hardships faced by a patient to access quality healthcare and poor patient outcome used as proxy indicators. It also points to the need to enhance access to healthcare to ensure early diagnosis and effective treatment for leishmaniasis patients including those who live in remote areas, in order to achieve the planned disease elimination targets. It also points towards the key challenges faced by a resource poor nation such as Bhutan in achieving universal health coverage and reaching the set goals for disease elimination. The findings underscore the need for a careful review of the national health care system and to address the deficiencies.

Identifiers

PMID32904486
PMCPMC7456484
OpenAlexW3080267302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.